Google Alert - "LSD1 inhibitor" OR "sickle cell disease" · Scour

First Louisiana patient home from sickle cell gene therapy

Fulcrum Therapeutics Reports Positive Pociredir Data in Sickle Cell Disease , Strong Cash ...

FULC: Pociredir showed strong efficacy and safety in sickle cell disease , with pivotal trial ...

Intellia files CRISPR drug after historic phase 3 readout

Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript

Value Trap or Opportunity? Fulcrum Therapeutics (FULC) Q1 2026 E

Novo Nordisk's Teen Pill Push and Buyback Blitz Come as Oral Wegovy Leaves Lilly in the Dust

Fulcrum Therapeutics Adds Josh Lehrer to Board as It Advances Sickle Cell Pipeline

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

FULC: Strong pociredir data and $333M cash position support clinical advancement into 2029

Fulcrum Therapeutics Highlights Q1 Results and Sickle Cell Progress

Fulcrum Therapeutics adds former Oxbryta developer to board

FULC) reported that as of the end of Q1 2026, the total amount of cash and marketable ...

[8-K] Fulcrum Therapeutics, Inc. Reports Material Event | FULC 8-K Filing

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors | News

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First ...

Fulcrum Therapeutics Appoints Dr. Josh Lehrer to Board of Directors

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

Ukwala families battle sickle cell stigma despite improved access to healthcare

Diaphyseal Tuberculosis of the Tibia in a Sickle Cell Anemia SS: A Case Report

Log in to enable infinite scrolling